13F HOLDINGS REPORT (Amended)
SR ONE CAPITAL MANAGEMENT, LP
Quarter ended Q2 2023 · Filed May 19, 2023 · Accession 0001910264-23-000003
Total Value
$268.5M
Positions
6
Other Managers
0
Confidential Omitted
No
Holdings (6)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | ARCELLX INC. | ACLX | 5,500,007 | $169.5M | 63.12% |
| 2 | DESIGN THERAPEUTICS INC | DSGN | 6,526,476 | $37.7M | 14.03% |
| 3 | MINERALYS THERAPEUTICS | MLYS | 1,794,600 | $28.1M | 10.47% |
| 4 | ARS PHARMACEUTICALS | SPRY | 4,012,903 | $26.1M | 9.73% |
| 5 | NKARTA INC. | NKTX | 1,333,333 | $4.7M | 1.76% |
| 6 | EFFECTOR THERAPEUTICS INC | 28202V108 | 6,822,114 | $2.4M | 0.89% |